98P Adjuvant aumolertinib in resected EGFR-mutated non-small cell lung cancer: A multiple-center real-world experience

Aumolertinib as a novel third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) has been shown to be efficacy in EGFR mutations and also CNS metastasis NSCLC. We aimed evaluate long-term safety of adjuvant aumolertinib postoperative patients. A total 215 patients who underwent radical lung cancer surgery with EGFR-sensitizing from four different medical centers were enrolled received 110 mg daily, the medication time (6months-36months) depended on pathological stage physical conditions. The disease-free survival (DFS), tolerability evaluated. study retrospectively analyzed pathologically confirmed adenocarcinoma, mutation-positive, Ia2–IIIa NSCLC (132 females, 87 males, ranging age 27 86 years, median 63). All followed for at least 6 months, 40 have up over 2 1 year. At data cutoff, all alive, only one patient had bone metastasis, no presented metastasis. 2-year DFS was 99%. During treatment, 69 (69/215, 32.1%) experienced drug-related adverse reactions. Rash (39/215, 18.1%), diarrhea (15/215, 7.0%), abnormal liver kidney function (12/215, 5.6%), mouse ulcer (11/215,5.1%). There grade ≥3 events that occurred, withdrew treatment due Based our previous study, we expanded number extended follow-up period. Our further demonstrates pronounced an excellent profile. Long term is ongoing investigate outcomes.